ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The PROTAC NJH-2–142 (Figure 4), which was based on EN106 and linked via an alkyl linker to dasatinib, demonstrated BCR-ABL degradation in K562 CML cell lines.